HanchorBio Inc.
Research HanchorBio Inc. (7827.TW) on Bullrun: market cap TWD 26.54B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker7827.TW
- ExchangeTW
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 26.54B
- Financial periodQ2 2026
- RevenueTWD 9.54M
- Net income-TWD 251.00M
- Free cash flow-TWD 242.31M
- Gross margin6.5%
Valuation Snapshot
latest market cap is TWD 26.54B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 26.54B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About HanchorBio Inc.
HanchorBio Inc. engages in the research and development of new anti-cancer drugs in Hong Kong and Mainland China. The companys product pipeline consists of HCB101, which is in phase II clinical trial to treat head and neck cancer, triple-negative breast cancer, gastric cancer, colorectal cancer, and small cell lung cancer; HCB301, which is in phase I clinical trial for the treatment of hematologic malignancies, head and neck cancer, and solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is HanchorBio Inc.'s market cap?
HanchorBio Inc.'s market capitalization is TWD 26.54B.
What does HanchorBio Inc. do?
HanchorBio Inc. engages in the research and development of new anti-cancer drugs in Hong Kong and Mainland China. The companys product pipeline consists of HCB101, which is in phase II clinical trial to treat head and neck cancer, triple-negative breast cancer, gastric cancer, colorectal cancer, and small cell lung cancer; HCB301, which is in phase I clinical trial for the treatment of hematologic malignancies, head and neck cancer, and solid tumors; and HCB303, which is in preclinical trial to treat hematologic malignancies, head and neck cancer, and solid tumors.